中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

9 records (took 0.018 seconds)

    Notch1 Decoy Antagonists Protect From Obesity-Induced Insulin Resistance and Fatty Liver
    2.
    发明申请
    Notch1 Decoy Antagonists Protect From Obesity-Induced Insulin Resistance and Fatty Liver 审中-公开
    Notch1诱饵拮抗剂保护免受肥胖诱导的胰岛素抵抗和脂肪肝

    公开(公告)号：US20160030513A1

    公开(公告)日：2016-02-04

    申请号：US14814407

    申请日：2015-07-30

    Applicant: Utpal Pajvani ,  Jan Kitajewski

    Inventor： Utpal Pajvani ,  Jan Kitajewski

    IPC: A61K38/17 ,  A61K45/06

    CPC classification number: A61K38/177 ,  A61K45/06 ,  A61K48/00 ,  C07K14/705 ,  C07K2319/30 ,  A61K2300/00

    Abstract: The present invention provides a method of treating a subject suffering from a fatty liver disease which comprises administering to the subject a Notch decoy protein or Jagged inhibitor in an amount effective to treat the subject's fatty liver disease.The present invention provides a composition comprising a pharmaceutically acceptable carrier and an amount of a Notch decoy protein or Jagged inhibitor effective to treat a fatty liver disease.The present invention provides a package comprising:(a) the pharmaceutical composition of the invention and (b) instructions for using the pharmaceutical composition of step (a) to treat the fatty liver disease.

    Abstract translation: 本发明提供了治疗患有脂肪肝疾病的受试者的方法，其包括以有效治疗受试者的脂肪肝疾病的量向受试者施用Notch诱饵蛋白或锯齿状抑制剂。 本发明提供了包含药学上可接受的载体和一定量的有效治疗脂肪肝疾病的Notch诱饵蛋白或锯齿状抑制剂的组合物。 本发明提供一种包装，其包含：（a）本发明的药物组合物和（b）使用步骤（a）的药物组合物治疗脂肪肝疾病的说明书。

    JAG1 EXPRESSION PREDICTS THERAPEUTIC RESPONSE IN NASH
    3.
    发明申请
    JAG1 EXPRESSION PREDICTS THERAPEUTIC RESPONSE IN NASH 有权

    公开(公告)号：US20210025003A1

    公开(公告)日：2021-01-28

    申请号：US16997194

    申请日：2020-08-19

    Applicant: Utpal Pajvani

    Inventor： Utpal Pajvani

    IPC: C12Q1/6883 ,  C12Q1/68 ,  G01N33/50

    Abstract: The present invention provides a method for treating a human subject afflicted with a metabolic disease with a pharmaceutical composition, comprising the steps of: (i) determining JAG1 expression level in the subject; (ii) identifying the subject as a predicted responder if JAG1 expression level is greater than 1.5 fg/ng 18S; and (iii) administering the pharmaceutical composition to the subject only if the subject is identified as a predicted responder.

    JAG1 expression predicts therapeutic response in NASH
    6.
    发明授权
    JAG1 expression predicts therapeutic response in NASH 有权

    公开(公告)号：US10801068B2

    公开(公告)日：2020-10-13

    申请号：US15768701

    申请日：2016-10-14

    Applicant: Utpal Pajvani

    Inventor： Utpal Pajvani

    IPC: C12Q1/6883 ,  C12Q1/68 ,  G01N33/50

    Abstract: The present invention provides a method for treating a human subject afflicted with a metabolic disease with a pharmaceutical composition, comprising the steps of: (i) determining JAG1 expression level in the subject; (ii) identifying the subject as a predicted responder if JAG1 expression level is greater than 1.5 fg/ng 18S; and (iii) administering the pharmaceutical composition to the subject only if the subject is identified as a predicted responder.

    Method of identifying responders to treatment with insulin sensitizers
    9.
    发明申请
    Method of identifying responders to treatment with insulin sensitizers 审中-公开
    识别胰岛素敏化剂治疗反应者的方法

    公开(公告)号：US20070098636A1

    公开(公告)日：2007-05-03

    申请号：US10578811

    申请日：2004-11-04

    Applicant: John Wagner ,  Utpal Pajvani ,  John Wagner

    Inventor： John Wagner ,  Utpal Pajvani ,  John Wagner

    IPC: A61K49/00

    CPC classification number: G01N33/6893 ,  A61K49/0004 ,  G01N33/74 ,  G01N2333/72 ,  G01N2800/042 ,  G01N2800/52

    Abstract: A patient who is a responder to a therapeutic treatment for insulin resistance or for one or more diseases associated with type 2 diabetes can be identified by the method of measuring the amount of HMW adiponectin and the amount of total adiponectin or LMW adiponectin in the patient's tissue (usually plasma or serum) before the therapeutic treatment commences; then commencing the therapeutic treatment; and finally measuring the amount of HMW adiponectin and the amount of either total adiponectin or LMW adiponectin in the patient's plasma or serum one or more times after commencement of the therapeutic treatment. The patient is predicted to be a responder to the therapeutic treatment if the ratio of the amount of HMW adiponectin to the amount of total adiponectin or LMW adiponectin increases after the therapeutic treatment commences.

    Abstract translation: 作为对胰岛素抵抗或与2型糖尿病相关的一种或多种疾病的治疗性治疗的反应者的患者可以通过测量患者组织中HMW脂连蛋白的量和总脂连蛋白或LMW脂联素的量的方法来鉴定 （通常为血浆或血清）; 然后开始治疗; 最后在治疗开始后测定HMW脂联素的量和患者血浆或血清中一次或多次的总脂联素或LMW脂联素的量。 如果在治疗开始后HMW脂联素的量与总脂连蛋白或LMW脂联素的量的比例增加，则患者被预测为治疗性应答者。

Patent Agency Ranking